Dynamics of HIV DNA reservoir seeding in a cohort of superinfected Kenyan women.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
27
08
2019
accepted:
16
12
2019
revised:
18
02
2020
pubmed:
6
2
2020
medline:
6
5
2020
entrez:
6
2
2020
Statut:
epublish
Résumé
A reservoir of HIV-infected cells that persists despite suppressive antiretroviral therapy (ART) is the source of viral rebound upon ART cessation and the major barrier to a cure. Understanding reservoir seeding dynamics will help identify the best timing for HIV cure strategies. Here we characterize reservoir seeding using longitudinal samples from before and after ART initiation in individuals who sequentially became infected with genetically distinct HIV variants (superinfected). We previously identified cases of superinfection in a cohort of Kenyan women, and the dates of both initial infection and superinfection were determined. Six women, superinfected 0.2-5.2 years after initial infection, were subsequently treated with ART 5.4-18.0 years after initial infection. We performed next-generation sequencing of HIV gag and env RNA from plasma collected during acute infection as well as every ~2 years thereafter until ART initiation, and of HIV DNA from PBMCs collected 0.9-4.8 years after viral suppression on ART. We assessed phylogenetic relationships between HIV DNA reservoir sequences and longitudinal plasma RNA sequences prior to ART, to determine proportions of initial and superinfecting variants in the reservoir. The proportions of initial and superinfection lineage variants present in the HIV DNA reservoir were most similar to the proportions present in HIV RNA immediately prior to ART initiation. Phylogenetic analysis confirmed that the majority of HIV DNA reservoir sequences had the smallest pairwise distance to RNA sequences from timepoints closest to ART initiation. Our data suggest that while reservoir cells are created throughout pre-ART infection, the majority of HIV-infected cells that persist during ART entered the reservoir near the time of ART initiation. We estimate the half-life of pre-ART DNA reservoir sequences to be ~25 months, which is shorter than estimated reservoir decay rates during suppressive ART, implying continual decay and reseeding of the reservoir up to the point of ART initiation.
Identifiants
pubmed: 32023326
doi: 10.1371/journal.ppat.1008286
pii: PPATHOGENS-D-19-01577
pmc: PMC7028291
doi:
Substances chimiques
DNA, Viral
0
env Gene Products, Human Immunodeficiency Virus
0
gag Gene Products, Human Immunodeficiency Virus
0
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1008286Subventions
Organisme : NIAID NIH HHS
ID : K25 AI155224
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM113246
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI038518
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI126623
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD094718
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
AIDS Res Hum Retroviruses. 2008 Sep;24(9):1221
pubmed: 18729772
Sci Transl Med. 2019 Oct 9;11(513):
pubmed: 31597754
PLoS One. 2012;7(3):e33948
pubmed: 22479485
J Virol. 2017 Jun 9;91(13):
pubmed: 28404854
Nature. 1997 May 8;387(6629):183-8
pubmed: 9144289
Mol Biol Evol. 2018 Dec 1;35(12):3041-3043
pubmed: 30351396
Science. 2014 Jul 11;345(6193):179-83
pubmed: 24968937
Nat Commun. 2018 Nov 16;9(1):4811
pubmed: 30446650
Bioinformatics. 2011 Feb 15;27(4):592-3
pubmed: 21169378
PLoS Pathog. 2007 Nov;3(11):e177
pubmed: 18020705
N Engl J Med. 2016 Jun 2;374(22):2120-30
pubmed: 27192360
PLoS Pathog. 2014 Mar 20;10(3):e1004010
pubmed: 24651464
Nat Med. 2016 Sep;22(9):1043-9
pubmed: 27500724
Cell Rep. 2017 Oct 17;21(3):813-822
pubmed: 29045846
J Infect Dis. 2015 Aug 15;212(4):596-607
pubmed: 25712966
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):E4987-96
pubmed: 24277811
Retrovirology. 2018 Jan 30;15(1):14
pubmed: 29378595
Nat Commun. 2019 Feb 13;10(1):728
pubmed: 30760706
Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8958-E8967
pubmed: 30185556
Nature. 2014 Aug 7;512(7512):74-7
pubmed: 25042999
J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):473-83
pubmed: 15021312
J Virol. 2003 May;77(10):5721-30
pubmed: 12719565
Nat Med. 2003 Jun;9(6):727-8
pubmed: 12754504
Curr HIV Res. 2010 Dec;8(8):596-601
pubmed: 21054252
Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16725-30
pubmed: 18936487
PLoS Pathog. 2013 Mar;9(3):e1003211
pubmed: 23516360
AIDS. 2018 Sep 24;32(15):2113-2118
pubmed: 30005008
Science. 2014 Aug 1;345(6196):570-3
pubmed: 25011556
AIDS. 2014 Sep 24;28(15):2281-6
pubmed: 25102090
J Infect Dis. 2015 Nov 1;212(9):1361-5
pubmed: 25877550
PLoS Pathog. 2013;9(8):e1003593
pubmed: 24009513
J Antimicrob Chemother. 2013 May;68(5):1169-78
pubmed: 23335199
Elife. 2016 Nov 15;5:
pubmed: 27855060
Bioinformatics. 2004 Jan 22;20(2):289-90
pubmed: 14734327
Open Forum Infect Dis. 2017 Sep 19;4(3):ofx173
pubmed: 30310821